VC investment in biopharma modalities continued its strategic consolidation trend in Q1 2025, with deal count decreasing 18.1% QoQ to 203 deals while maintaining relatively stable funding at $7.4 billion. The trailing 12-month funding reached $31.5 billion, representing a significant 20.6% YoY growth despite market headwinds, according to PitchBook’s Q1 2025 analysis. While exit activity moderated with 18 transactions (down 21.7% QoQ), strategic acquisitions like IDRx’s $1.15 billion sale to GSK created significant investor returns.
Read the full article: PitchBook: Q1 2025 Biopharma Modalities VC Trends //
Source: https://pitchbook.com/news/reports/q1-2025-biopharma-modalities-vc-trends